QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)

Moderna (MRNA) Stock Price, News & Analysis

$99.44
+11.85 (+13.53%)
(As of 02/22/2024 ET)
Today's Range
$91.06
$101.73
50-Day Range
$85.37
$115.44
52-Week Range
$62.55
$163.24
Volume
11.34 million shs
Average Volume
4.65 million shs
Market Capitalization
$37.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$123.96

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.12 Rating Score
Upside/​Downside
24.7% Upside
$123.96 Price Target
Short Interest
Healthy
6.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.70mentions of Moderna in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$10.73 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.39) to ($5.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

78th out of 934 stocks

Biological Products, Except Diagnostic Industry

13th out of 160 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Why Moderna Stock Is Jumping Today
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Moderna Adds 6% On Better-than-expected Quarterly Results
Moderna CEO's 2024 goal is to increase US vaccination rate
Why Earnings Season Could Be Great for Moderna (MRNA)
MRNA Sep 2024 115.000 call
Moderna (MRNA) to Release Earnings on Thursday
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
3,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$123.96
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+24.7%
Consensus Rating
Hold
Rating Score (0-4)
2.12
Research Coverage
17 Analysts

Profitability

Net Income
$8.36 billion
Pretax Margin
-25.84%

Debt

Sales & Book Value

Annual Sales
$9.09 billion
Cash Flow
$26.03 per share
Book Value
$49.78 per share

Miscellaneous

Free Float
321,422,000
Market Cap
$37.91 billion
Optionable
Optionable
Beta
1.69

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Moderna was last updated on Monday, February 19, 2024 at 8:44 PM.














MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

17 Wall Street analysts have issued 1-year target prices for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they anticipate the company's stock price to reach $123.96 in the next year. This suggests a possible upside of 24.7% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 on January 1st, 2024. Since then, MRNA shares have decreased by 0.0% and is now trading at $99.44.
View the best growth stocks for 2024 here
.

Are investors shorting Moderna?

Moderna saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 20,880,000 shares, a drop of 9.5% from the January 15th total of 23,070,000 shares. Based on an average daily trading volume, of 4,650,000 shares, the short-interest ratio is presently 4.5 days. Approximately 6.3% of the company's stock are sold short.
View Moderna's Short Interest
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) released its earnings results on Thursday, August, 3rd. The company reported ($3.62) EPS for the quarter, topping analysts' consensus estimates of ($3.84) by $0.22. The firm had revenue of $344 million for the quarter, compared to the consensus estimate of $307.67 million. Moderna had a negative trailing twelve-month return on equity of 2.14% and a negative net margin of 38.00%. The firm's quarterly revenue was down 92.8% on a year-over-year basis. During the same period last year, the business earned $5.24 earnings per share.

What guidance has Moderna issued on next quarter's earnings?

Moderna issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.97%), Vanguard Group Inc. (8.89%), Capital World Investors (0.95%), The Manufacturers Life Insurance Company (0.93%), Norges Bank (0.92%) and Coatue Management LLC (0.86%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 2/22/2024 by MarketBeat.com Staff

From Our Partners